A U.S. cannabis company has made a bid to acquire Aurora Cannabis Inc., a firm based in Edmonton. Aurora has established a special committee to evaluate this unsolicited offer following the announcement by Curaleaf Holdings Inc. of their intention to acquire all shares of Aurora.
If successful, the acquisition would result in a combined cannabis enterprise operating in 17 countries across Europe, North America, and other global markets, as per Curaleaf. Despite attempting private negotiations with Aurora’s leadership without success, Curaleaf, based in Stamford, Connecticut and listed on the Toronto Stock Exchange, has decided to publicize their proposal.
Curaleaf expressed disappointment with Aurora’s board for not engaging in meaningful discussions after receiving a formal offer letter from Curaleaf’s CEO on June 23. Subsequent attempts to communicate were also allegedly rebuffed by Aurora. Curaleaf aims to involve Aurora’s shareholders directly due to the perceived value and strategic benefits of the proposed merger.
Curaleaf has proposed a payment of $4 US per share to Aurora shareholders, along with an additional $0.75 US in cash for each Aurora share. Aurora confirmed receipt of Curaleaf’s letters outlining the acquisition proposals but disputed Curaleaf’s claim of refusal to engage. Aurora’s independent director maintained communication with Curaleaf’s CEO, indicating Aurora’s commitment to its existing business strategy.
Aurora plans to convene a special committee of independent directors to review the offer’s merits for stakeholders. While expressing interest in Curaleaf’s bid, commentators have noted that the current offer undervalues Aurora’s long-term potential. The companies anticipate significant synergies from the merger, with Curaleaf expecting annual cost savings of at least $40 million US.
Curaleaf’s CEO emphasized the benefits of combining the companies, highlighting the synergies between Curaleaf’s global distribution network and Aurora’s strong international presence in medical cannabis. The merger is seen as a positive opportunity for both Curaleaf and Aurora shareholders to participate in an expanded global platform and leverage favorable U.S. regulatory trends.